FibroBiologics, Inc. Common Stock (FBLG) Stock Price
FBLGStock
$1.44−88.39%52W
Market Cap$9.59M
P/E—
PEG Ratio—
Div yield—
Beta1.70
FBLG Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-85.01%
Price vs S&P 500 (4W)80.62%
VGM Score45.79
FBLG Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.93 | -$0.66 | +29.03%(+$0.27) | |
| Q1 2026 | -$1.35 | -$1.33 | +1.85%(+$0.02) | |
| Q4 2025 | -$2.00 | -$0.60 | +70.00%(+$1.40) | |
| Q3 2025 | -$2.30 | -$2.60 | -13.04%(-$0.30) | |
| Q2 2025 | -$2.25 | -$2.40 | -6.67%(-$0.15) |
FBLG Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.00
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FBLGFibroBiologics, Inc. Common Stock | — | — | C | $1.44 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About FibroBiologics, Inc. Common Stock
FibroBiologics Inc is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. The company's pipeline comprises four candidates: CYWC628, CYPS317, CYMS101, and CybroCell, with additional exploration in oncology and age-related conditions, including novel approaches to reverse thymic involution.